Please login to the form below

Not currently logged in
Email:
Password:

Janssen

This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.

J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine

J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine

A deal between Janssen, J&J’s Belgian subsidiary, and Cidara Therapeutics will see Janssen paying $27m upfront for access to a new class of drugs, antiviral conjugates. ... At that point, Janssen will take over, after reimbursing Cidara for the R&D

Latest news

More from news
Approximately 141 fully matching, plus 402 partially matching documents found.

Latest Intelligence

  • Unlocking the potential of precision medicine in oncology Unlocking the potential of precision medicine in oncology

    Joaquín Casariego García-Lubén talks to PME about how Janssen is driven by the premise of providing personalised treatment solutions in cancer care. ... Joaquín Casariego García-Lubén is EMEA Therapeutic Area Lead Oncology, The Janssen

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    Pfizer also cited a Janssen brochure that allegedly implied the biosimilar Inflectra is not interchangeable with Remicade and may pose a safety risk.

  • The first, my last, my everything The first, my last, my everything

    It’s a subtle but important nuance. It’s a similar story elsewhere, with companies like Roche, Janssen and MSD ‘partnering with patients’ to understand their needs and identify opportunities for

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Katrin Haeverans, EPAD LCS and POC platform support, Janssen said: “EPAD has been built to facilitate proof-of-concept trials. ... Sir Simon Lovestone. After 18 years in old age psychiatry and dementia research in academia, Sir Simon Lovestone joined

More from intelligence
Approximately 5 fully matching, plus 52 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 27 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 30 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics